OneSource Specialty Pharma Ltd
ONESOURCE NSE
OneSource Specialty Pharma Ltd
HealthcareNSE: ONESOURCE BSE: 544292 Pharmaceuticals
Key Fundamentals
SmallcapPharmaceuticalsHealthcareMarket Cap
₹17,854 Cr
Volatility
Moderate
P/E Ratio
-365.8
EBITDA
₹294 Cr
Return on Equity
-0.29%
Debt to Equity
0.26
Book Value
₹508.58
52W High
₹1,925
52W Low
₹1,057
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view OneSource Specialty Pharma Ltd insights
39 extracted metrics + investor summaries across FY21–FY26.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Weaknesses
5- Stock is trading at 3.10 times its book value
- Company has low interest coverage ratio.
- Company has a low return on equity of -2.39% over last 3 years.
- Promoters have pledged 37.2% of their holding.
- Company has high debtors of 177 days.
Growth Rate
Revenue Growth
-2.78% ↘
Net Income Growth
444.34% ↗
Cash Flow Change
36.71% ↗
ROE
-99.69% ↘
ROCE
-103.78% ↘
EBITDA Margin (Avg.)
-38.10% ↘
AI Analysis — Bull vs Bear
anthropic claude-opus-4.6 3d agoAI opinion · based on fundamentals
Risk high
OneSource Specialty Pharma Ltd is a small-cap healthcare company with a market cap of ₹17,667 Cr that has delivered strong historical sales growth (3-year CAGR of 232%) but remains loss-making with a negative PE of -361.8 and negative ROE of -2% over 3 years. The company carries significant governance and financial risks including 37.2% promoter pledge and high debtor days of 177.
Bull Case 7
- Exceptional 3-year compounded sales growth of 232% indicates rapid revenue scale-up in specialty pharma segment
- 5-year compounded sales growth of 131% demonstrates sustained top-line momentum over a longer horizon
- TTM sales growth of 4% shows the company is still growing revenue, albeit at a decelerating pace
- 3-year compounded profit growth of 24% suggests improving profitability trajectory despite current losses
- 5-year compounded profit growth of 8% indicates gradual narrowing of losses over the medium term
- Price-to-book ratio of 3.02 is not excessively high for a specialty pharma company with high revenue growth history
- Operating in the specialty pharma segment which typically commands higher margins once scale is achieved
Bear Case 8
- Negative PE ratio of -361.8 confirms the company is currently loss-making with no earnings to support valuation
- Negative ROE of -2% over 3 years and -10% over 5 years indicates persistent destruction of shareholder value
- Promoters have pledged 37.2% of their holding, creating risk of forced selling and governance concerns
- High debtor days of 177 signals poor working capital management and potential collection risks
- TTM profit decline of -142% shows losses are widening significantly in the most recent period
- Low interest coverage ratio indicates the company may struggle to service its debt obligations
- Stock has declined 18% over 1 year, reflecting negative market sentiment and capital erosion for investors
- Zero dividend yield with no returns to shareholders while the company continues to operate at a loss
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
anthropic claude-opus-4.6 1d ago Positives 3
- Q1FY26 profit turnaround Jul 26
Consolidated net profit of ₹292.97 million in Q1FY26 vs a loss of ₹26.84 million YoY. Revenue rose 37% YoY to ₹4,490.23 million.
- Formycon biosimilars manufacturing deal Jul 15
Strategic partnership with Formycon AG announced July 14, 2026 to manufacture biosimilars for global markets using OneSource's five FDA/EMA-approved Bengaluru facilities.
- Supply delay has no impact Jul 9
Dr. Reddy's Labs supply delay confirmed not to disrupt operations. Strong client demand continues with expansion plans underway to meet future requirements.
Neutral 2
- Senior management personnel change Jul 25
Ravi Kumar resigned and Preeti Kalra was designated as SMP effective July 24, 2026.
- Q1FY27 earnings call scheduled Jul 21
Earnings call to discuss unaudited Q1FY27 results hosted on July 25, 2026 at 10:00 AM IST.
TL;DR: OneSource delivered a strong Q1FY26 with a profit turnaround and 37% revenue growth, signalling improving execution. The Formycon partnership adds a credible global biosimilar manufacturing revenue stream. No material headwinds are visible, though a senior management change warrants monitoring. The trend is clearly improving with expansion plans and diversified client demand supporting near-term momentum.
Quarterly Results
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 34 | 56 | 73 | 292 | 334 | 393 | 426 | 327 | 376 | 290 | 428 | 449 |
| Expenses | 72 | 67 | 76 | 228 | 257 | 251 | 243 | 239 | 269 | 273 | 336 | 326 |
| Operating Profit | -39 | -10 | -3 | 64 | 77 | 142 | 183 | 88 | 106 | 17 | 92 | 123 |
| OPM % | -114% | -19% | -3.8% | 22% | 23% | 36% | 43% | 27% | 28% | 6% | 21% | 27% |
| Other Income | -32 | -74 | 3 | -1 | -1 | -94 | 2 | 2 | 3 | -2 | 2 | 0 |
| Interest | 25 | 26 | 20 | 42 | 45 | 46 | 33 | 27 | 34 | 38 | 23 | 31 |
| Depreciation | 18 | 20 | 20 | 68 | 68 | 69 | 68 | 68 | 70 | 70 | 72 | 72 |
| PBT | -114 | -130 | -40 | -47 | -37 | -67 | 83 | -4 | 6 | -93 | 0 | 20 |
| Tax % | 0% | 0% | 0% | -88% | 12% | 4% | -19% | -96% | -83% | -5% | -1630% | -23% |
| Net Profit | -114 | -130 | -40 | -6 | -42 | -69 | 98 | 0 | 10 | -89 | 5 | 25 |
| EPS in Rs | — | — | — | — | — | -6.02 | 8.61 | -0.02 | 0.92 | -7.74 | 0.4 | 2.18 |
Profit & Loss
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|
| Sales | 21 | 132 | 39 | 172 | 1,445 | 1,422 | 1,543 |
| Expenses | 93 | 229 | 199 | 254 | 978 | 1,117 | 1,204 |
| Operating Profit | -71 | -97 | -161 | -82 | 467 | 304 | 339 |
| OPM % | -334% | -73% | -415% | -48% | 32% | 21% | 22% |
| Other Income | 1 | 4 | -526 | -143 | -94 | 5 | 2 |
| Interest | 16 | 68 | 48 | 89 | 166 | 122 | 126 |
| Depreciation | 34 | 70 | 66 | 76 | 274 | 279 | 283 |
| PBT | -121 | -231 | -800 | -391 | -68 | -92 | -67 |
| Tax % | 0% | 0% | 0% | 0% | -73% | -20% | — |
| Net Profit | -121 | -231 | -800 | -391 | -18 | -74 | -49 |
| EPS in Rs | — | — | — | — | -1.57 | -6.44 | -4.24 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 2 | 3 | 4 | 4 | 11 | 11 |
| Reserves | 774 | 1,009 | 781 | 392 | 5,869 | 5,820 |
| Borrowings | 386 | 1,154 | 864 | 562 | 772 | 1,504 |
| Other Liabilities | 96 | 276 | 365 | 468 | 1,005 | 875 |
| Total Liabilities | 1,258 | 2,442 | 2,015 | 1,426 | 7,657 | 8,210 |
| Fixed Assets | 633 | 1,231 | 1,361 | 863 | 6,118 | 6,233 |
| CWIP | 431 | 490 | 334 | 188 | 218 | 314 |
| Investments | 0 | 0 | 4 | 20 | 16 | 16 |
| Other Assets | 195 | 722 | 314 | 356 | 1,305 | 1,648 |
| Total Assets | 1,258 | 2,442 | 2,015 | 1,426 | 7,657 | 8,210 |
Cash Flow
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Operating | -118 | -416 | -163 | -107 | -68 | 9 |
| Investing | -207 | -692 | -68 | 511 | -201 | -495 |
| Financing | 381 | 1,162 | 118 | -391 | 412 | 359 |
| Net Cash Flow | 56 | 54 | -112 | 13 | 143 | -127 |
| Free Cash Flow | -325 | -1,071 | -207 | -171 | -196 | -561 |
| CFO/OP | 164 | 430 | 108 | 130 | -13 | 6 |
Ratios
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor Days | 38 | 65 | 36 | 117 | 105 | 177 |
| Inventory Days | 87 | 1,805 | 615 | 258 | 222 | 360 |
| Days Payable | 762 | 410 | 420 | 163 | 147 | 307 |
| Cash Conversion Cycle | -637 | 1,461 | 232 | 212 | 180 | 230 |
| Working Capital Days | -2,392 | -1,291 | -6,745 | -877 | -58 | -29 |
| ROCE % | — | -10% | -12% | -12% | 6% | 1% |
Documents
1
Announcement under Regulation 30 (LODR)-Press Release / Media Release
4 May - Partner received Health Canada approval for generic semaglutide; OneSource will support commercial supply from Bengaluru. 4 May - Partner received Health Canada approval for generic semaglutide; OneSource will support commercial supply from Bengaluru.
2
Board Meeting Intimation for Intimation Regarding Board Meeting Under Regulation 29 Of SEBI (LODR), Regulations, 2015
7 May - Board meeting on May 13, 2026 to approve audited Q4 and FY2026 results; trading window closed from April 1. 7 May - Board meeting on May 13, 2026 to approve audited Q4 and FY2026 results; trading window closed from April 1.
3
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
7 May - Regarding earnings call to be held on May 13, 2026 7 May - Regarding earnings call to be held on May 13, 2026
4
General-Update
28 Apr - OneSource SPD facility received EU GMP certificate on April 27, 2026. 28 Apr - OneSource SPD facility received EU GMP certificate on April 27, 2026.
5
Announcement under Regulation 30 (LODR)-Press Release / Media Release
29 Apr - Dr. Reddy’s received Health Canada approval for generic Semaglutide Injection; OneSource will support commercial manufacturing. 29 Apr - Dr. Reddy’s received Health Canada approval for generic Semaglutide Injection; OneSource will support commercial manufacturing.
Frequently Asked Questions about OneSource Specialty Pharma Ltd
What does OneSource Specialty Pharma Ltd do?
Incorporated in 2007, OneSource Specialty Pharma Ltd is in the research, development, manufacture and commercialisation of bio
logical drug products in various injectable formats. It also offers end-to-end CDMO
services across all phases of pre-clinical
and clinical development and commercial
...
Where is OneSource Specialty Pharma Ltd (ONESOURCE) listed?
OneSource Specialty Pharma Ltd is listed on the Indian stock exchanges. It is listed on NSE: ONESOURCE and BSE: 544292. You can view its live share price, financials, and ratios on Tapetide.
Which sector does OneSource Specialty Pharma Ltd belong to?
OneSource Specialty Pharma Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of OneSource Specialty Pharma Ltd?
OneSource Specialty Pharma Ltd has a market capitalisation of approximately ₹17853.79 Cr. Based on this, it is classified as a Mid Cap stock.
What is the PE ratio of OneSource Specialty Pharma Ltd?
The Price-to-Earnings (PE) ratio of OneSource Specialty Pharma Ltd is -365.80. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of OneSource Specialty Pharma Ltd?
Over the past 52 weeks, OneSource Specialty Pharma Ltd has traded between a low of ₹1,057 and a high of ₹1,925. This range helps investors understand the stock's price volatility and recent trading levels.
What is the Return on Equity (ROE) of OneSource Specialty Pharma Ltd?
OneSource Specialty Pharma Ltd has a Return on Equity (ROE) of -0.29%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research OneSource Specialty Pharma Ltd on Tapetide?
On Tapetide, you can view OneSource Specialty Pharma Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.
Company Information
Incorporated in 2007, OneSource Specialty Pharma Ltd is in the research, development, manufacture and commercialisation of bio logical drug products in various injectable formats. It also offers end-to-end CDMO services across all phases of pre-clinical and clinical development and commercial supply of biologics[1]